ctDNA in HER2+ EBC Neoadjuvant Treatment
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- Status
- RECRUITING
- Phase
- PHASE3
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
- Status
- COMPLETED
- Phase
- PHASE1
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
HB1801 Combined Treatment of HER2-positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE3
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
- Status
- COMPLETED
- Phase
- N/A
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
- Status
- RECRUITING
- Phase
- PHASE2
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Status
- RECRUITING
- Phase
- PHASE3